EGFR and breast cancer: In this study, MCF-7 breast cancer cells enriched in phosphorylated EGFR and HER2, cultured in a pro- (LPS + INF-γ) or conflicting- (LPS + INF-γ + IL-4) inflammatory environment, released EVs that increased the survival and viability of primary human monocytes.